Tag: Government Regulatory Contexts

Modern pharmaceutical manufacturing requires a shift from reactive problem-solving to proactive risk mitigation through structured frameworks that ensure patient safety and product efficacy across the global supply chain.

Overseeing the intricate web of global providers for raw materials and contract services is essential for ensuring product safety and maintaining a resilient pharmaceutical supply chain in a volatile market.

Far from being mere regulatory hurdles, internal and external Good Manufacturing Practice assessments serve as vital catalysts for institutional growth and the pursuit of operational perfection in pharmaceutical production.

Technology-Enabled Meaningful Patient Outcomes – TEMPO has been launched by the US Food and Drug Administration - FDA which is a pilot that looks...

The federal government has formally withdrawn the Biden-era minimum staffing mandates for nursing homes and long-term care operators, marking a significant repeal that reshapes...

UK Life Sciences Sector Plan Sets Sights on Global Top 3 by 2035 The UK Government has laid out a bold ambition: to become Europe’s...

Government Unveils Life Sciences Roadmap for Growth and Innovation London, July 2025 - The UK Government has officially launched its new UK Life Sciences Sector...